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Older age represents an adverse prognostic factor in Hodgkin lymphoma 
(HL). In fact, although in the last decades HL survival has improved also in 
patients above 60 years of age,1 lower 5-year overall survival (OS) rates (40-
65%) and progression free survival (PFS)/freedom from treatment failure rates 
(44-60%) have been observed.2-4 Poor outcomes in older patients are likely due 
to several factors. First, elderly patients have more comorbidities which can 
lead to increased toxicity of chemotherapeutic regimens, can compromise dose-
intensity or, in some cases, make the use of polychemotherapy impossible.5,6, 
Secondly, HL appears to have a different biology in older patients: in fact, an 
increased frequency of mixed cellularity subtype and Epstein Barr virus-related 
disease have been observed. Moreover, older patients often present with “B” 
symptoms.2 The treatment of relapsed/refractory (R/R) elderly HL patients is 
challenging. In a previous retrospective study from German Hodgkin Study 
Group, responses and survival of patients above 60 years of age affected by 
R/R HL were analyzed. Best responses were observed with conventional 
chemo-radiotherapy; in fact, CR rates of 30%, 59% and 12% were registered 
after treatment with intensified salvage treatments, conventional chemotherapy 
and/or salvage radiotherapy, and palliative approaches, respectively; OS was 
10 months, 41 months and 7 months, respectively.7 
Recent retrospective studies demonstrated the efficacy of brentuximab 
vedotin (BV) in older patients affected by R/R HL, although duration of response 
appeared to be quite short.8,9 
We present a single-arm, open-label, multicenter, phase 2 clinical trial, 
aimed at evaluating the antitumor efficacy and safety of BV as first salvage 
therapy in elderly patients with R/R HL (FIL_BVHD01). Patients aged ≥60 
years, who were not suitable for high dose chemotherapy, were eligible if 
affected by histologically confirmed CD30+ HL at first relapse or with primary 
refractory disease. The study involved 5 Italian Centers adhering to the Italian 
Lymphoma Foundation (Fondazione Italiana Linfomi, FIL) and was conducted in 
accordance with the Declaration of Helsinki. The study protocol was approved 
by the Ethical Committee of each participating site. Written informed consent 
was obtained by patients before any study procedure. The trial was registered 
3 
 
at www.clinicaltrials.gov, NCT02227433, and given the EudraCT number 2013-
004109-24.  
Treatment consisted in 1.8 mg/kg BV administered as a single outpatient 
intravenous infusion on Day 1 of each 21-day treatment cycle, for a maximum of 
16 cycles. The efficacy of single agent BV was measured by overall objective 
response rate (ORR, sum of complete response [CR] and partial response [PR] 
rates). Secondary endpoints were CR rate, disease free survival (DFS), 1-year 
PFS, 1-year OS and safety and tolerability of BV. OS was calculated from start 
of treatment to the date of death due to any cause and was censored at the last 
date the patient was known to be alive. DFS was estimated for patients who 
achieved a CR as time to relapse or death as a result of lymphoma or acute 
toxicity of treatment from first documentation of response. PFS was calculated 
as the time from the beginning of treatment until lymphoma progression or 
death due to any cause. Responses were determined using the Revised 
Response Criteria for Malignant Lymphoma.10 
Any adverse event (AE) occurred during treatment was encoded according 
to NCI Common Terminology Criteria for AEs v. 4.03. Demographics and 
patients’ characteristics were summarized by descriptive statistics and survival 
functions were estimated by using the Kaplan-Meier method. Statistical 
analyses were performed with Stata 11 (StataCorp LP, TX).  
Twenty patients were enrolled. Eighteen patients were evaluable for 
safety analysis (2 screening failure) and 17 for efficacy analysis (one patient 
neither was not primary refractory nor at first relapse). Nine males and 9 
females with a median age of 73 years (range 61.2-85.7) underwent BV 
therapy. Median time from diagnosis to BV treatment was 1 year and median 
time from last treatment to BV administration was 6 months. All patients’ 
characteristics are summarized in Table 1. Patients underwent a median of 7 
cycles of BV monotherapy (range 1-16). Two patients (12%) completed the 
therapeutic program receiving the 16 scheduled cycles of treatment, 7 patients 
discontinued treatment early due to lack of response or progression of the 
disease, 7 for toxicity and 1 patient was lost to follow-up. 
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Best response was reached at 4th cycle of BV therapy. ORR was 52.9% 
(9/17 patients) with a CR rate of 23.5% (4/17 patients). With a median follow-up 
of 24.9 months, median PFS was 8.8 months and median OS was 21.7 months. 
1-year PFS and OS were 40% and 68.8%, respectively (Figure 1 and Figure 2). 
Median time to next treatment was 2 months. Median DFS was 3.9 months: 
among the four patients who achieved a CR, 3 relapsed (at 2.8, 3.4 and 4.4 
months, respectively) while one patient is still in CR 16.4 months after end of 
treatment. 
The most common AEs were hematological: 5 cases (27%) of neutropenia 
(1 grade 1, 2 grade 2, 2 grade 3) and one grade 3 thrombocytopenia (5%) were 
observed. The most frequent extra-hematological toxicity was neuropathy, 
which occurred in 6 patients (33%) starting from cycle 2 (2 grade 1, 3 grade 2, 1 
grade 3). Three patients (16%) experienced hepatic toxicity (2 grade 2, 1 grade 
3), while skin rash occurred in 4 patients (22%) and gastric symptoms in 3 
patients (16%). Overall, 7 serious adverse events (SAE) and 2 suspected 
unexpected serious adverse reactions (SUSAR) were observed in 9 patients 
(50%), 6 of them judged related to BV. SAEs included 3 infectious 
complications, 3 cases of polyneuropathy, and 1 case of nausea/vomiting; 
SUSARs included 1 amylase and lipase elevation and 1 stroke. All the SAEs 
lead to treatment discontinuation. 
Currently, no standard second-line treatment is available in this setting of 
elderly R/R HL. In some selected cases, high-dose chemotherapy followed by 
ASCT can represent a curative option. Nevertheless, most of elderly patients 
are not eligible to high dose chemotherapy due to comorbidities or poor 
performance status. In such patients, a non-chemotherapeutic approach could 
represent the best treatment option. 
Efficacy and safety of BV have been demonstrated also in older patients 
as first-line treatment approach: despite high ORR and CR rate (92% and 73%, 
respectively), responses were not durable: in fact, median PFS was 10.5 
months.11  
A recent retrospective study evaluated the effectiveness and tolerability 
of BV in R/R HL patients: an ORR of 74%, median PFS of 15.1 months and 
5 
 
median OS of 17.8 months were observed. The most common AEs included 
leukopenia, anemia, and diarrhea. The documented incidence of peripheral 
neuropathy during BV treatment was only 9.6%.9   
In our study, we observed a lower ORR (52.9%) and PFS (8.8 months); 
these inferior outcomes could be due to the significantly higher median age of 
our patient population (73 vs 66.7 years), with all the limitations to compare 
efficacy with effectiveness. We also observed a higher incidence of peripheral 
neuropathy (33.3%), which is indeed in line with data from the phase II pivotal 
trial (42%);12 this discrepancy could be explained by the retrospective nature of 
Bröckelmann and colleagues’ study: it is possible that such AEs were 
underreported.9 Of note, we observed a high rate of AEs which led to 
hospitalization, which suggests that this subset of frail patients should be 
carefully monitored during treatment with BV. 
To our knowledge, our study is the first trial evaluating efficacy and safety 
of BV in elderly patients affected by HL in first relapse or refractory to first line 
treatment. The main limitations of the study are represented by the lack of a 
control group and the lack of frailty and geriatric assessment. However, one 
inclusion criteria was ECOG performance status ≤1 to guarantee patient 
capacity to perform activities of daily living. 
We observed a low rate of durable responses in a population of patients who 
were not heavily pretreated. Moreover, only two patients (12%) were able to 
complete the 16 scheduled cycles of treatment; this could suggest that the 
optimal number of cycles for older patients should be lower. As regarding 
toxicity, results were unexpected on the basis of previous reports:11,12 earlier 
dose reductions of BV to improve tolerability should be considered.  With a 
median age of 73, combination chemotherapy could still be considered in this 
population, or appealing strategies could include checkpoint inhibition alone or 
in combination with BV.13 However, the small sample size could have biased 
study results. Therefore, further studies are needed to identify the subset of 
patients who could more benefit from treatment with BV, and case-control 
studies are needed to compare BV with other therapeutic regimens in this 
specific population. Altogether, multicenter collaborations that integrate novel 
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agents and incorporate formal assessments of functional status to tailor therapy 
on a patient-specific basis will be critical to the successful study of and 
improved outcomes for older patients with HL. 
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Table 1. Patients’ characteristics (n = 18). 
 
Age 
Median (range), years  
 
73 (61.2-85.7) 
Sex, N 
Male 
Female 
 
9 
9 
Stage (Ann Arbor), N 
At diagnosis: 
    I 
    II 
    III 
    IV 
 
At time of BV treatment: 
    I 
    II 
    III 
    IV 
 
 
2 
0 
7 
9 
 
 
1 
2 
8 
7 
Performance status at BV treatment 
(ECOG), N 
0 
1 
 
 
11 
7 
Time I diagnosis-BV, median (range) 
 
Time last treatment-BV, median 
(range) 
 
1 year [2 mos-21 yrs] 
 
6 mos [1 mo-20 yrs] 
Last treatment, N 
ABVD/MBVD  
VBM 
COPP 
 
13 (2 plus RT) 
2 
2 
10 
 
gemcitabine 1 
Response to last treatment, N 
Refractory 
Relapsed 
 
6 
12 
ECOG: Eastern Cooperative Oncology Group, ABVD: doxorubicin, bleomycin, 
vinblastine, dacarbazine, MBVD: liposomal doxorubicin, bleomycin, vinblastine, 
dacarbazine, VBM: vinblastine, bleomycin, methotrexate, COPP: 
cyclophosphamide, vincristine, procarbazine and prednisone, RT: radiotherapy. 
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Figure Legends 
Figure 1. Overall Survival (OS). 
Figure 2. Progression Free Survival (PFS). 
 
 
 
 
 
 
 
 
 


